We are comparing Taiwan Liposome Company Ltd. (NASDAQ:TLC) and Bioblast Pharma Ltd. (NASDAQ:ORPN) on their dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation. They both are Biotechnology companies, competing one another.
Earnings & Valuation
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Taiwan Liposome Company Ltd. | N/A | 0.00 | N/A | -0.51 | 0.00 |
Bioblast Pharma Ltd. | N/A | 0.00 | 3.33M | -1.00 | 0.00 |
Table 1 showcases the top-line revenue, earnings per share (EPS) and valuation of Taiwan Liposome Company Ltd. and Bioblast Pharma Ltd.
Profitability
Table 2 has Taiwan Liposome Company Ltd. and Bioblast Pharma Ltd.’s return on equity, return on assets and net margins.
Net Margins | Return on Equity | Return on Assets | |
Taiwan Liposome Company Ltd. | 0.00% | 0% | 0% |
Bioblast Pharma Ltd. | 0.00% | -101.1% | -88.2% |
Institutional & Insider Ownership
Institutional investors owned 2.46% of Taiwan Liposome Company Ltd. shares and 19.5% of Bioblast Pharma Ltd. shares. Comparatively, Bioblast Pharma Ltd. has 36.85% of it’s share owned by insiders.
Performance
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
Performance (W) | Performance (M) | Performance (Q) | Performance (HY) | Performance (Y) | Performance (YTD) | |
Taiwan Liposome Company Ltd. | -0.5% | -2.14% | -6.74% | 0% | 0% | 8.18% |
Bioblast Pharma Ltd. | -6.62% | 15.98% | -2.31% | 0.79% | -50.58% | 64.13% |
For the past year Taiwan Liposome Company Ltd.’s stock price has smaller growth than Bioblast Pharma Ltd.
Summary
On 4 of the 6 factors Taiwan Liposome Company Ltd. beats Bioblast Pharma Ltd.
Bioblast Pharma Ltd., a clinical-stage biotechnology company, focuses on the development of clinically meaningful therapies for patients with rare and ultra-rare genetic diseases. It develops Trehalose 90mg/mL IV solution, a protein stabilizer and autophagy enhancer to treat patients with oculopharyngeal muscular dystrophy and spinocerebellar ataxia type 3. The company was founded in 2012 and is headquartered in Tel Aviv, Israel.
![](/free-report.png)
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.